| Issue Date | Title | Author(s) |
| 2024 | Assessment of the correction of neuroretinal changes using 2-ethyl-6-methyl-3- hydroxypyridinium N-acetyltaurinate in the modeling of POAG | Efimenko, S. V.; Korokin, M. V.; Gudyrev, O. S.; Danilenko, L. M.; Korokina, L. V. |
| 2022 | Combined anti-mediator therapy for severe destructive forms of acute necrotizing pancreatitis in rats | Firsova, T. I.; Danilenko, L. M.; Chub, A. V.; Malyutina, E. S.; Druzhikin, L. V. |
| 2019 | Combined use of arginase II inhibitors and tadalafil for the correction of monocrotaline pulmonary hypertension | Koklin, I. S.; Danilenko, L. M. |
| 2020 | Comparative study of the pharmacological effects of Venarus Plus, Venarus, and Detralex on L-NAME-induced endothelial dysfunction, venous tone and platelet aggregation | Lukyanova, Y. S.; Gureev, V. V.; Kolesnichenko, P. D.; Danilenko, L. M.; Gudyrev, O. S.; Pokrovskaya, T. G. |
| 2018 | Doxorubicin-associated Cardiomyopathy: New Approaches to Pharmacological Correction Using 3-(2,2,2-trimethylhydrazinium) Propionate Derivatives | Danilenko, L. M. |
| 2019 | Effect of multipotent mesenchymal stromal cells secretome on imiquimod-induced psoriasis in rats | Nadezhdina, N. A.; Nadezhdin, S. V.; Bondarev, V. P.; Mycic, A. V.; Burda, Yu. E.; Pokrovskiy, M. V.; Danilenko, L. M.; Peresypkina, A. A. |
| 2017 | Effect of pharmacological preconditioning with incretinomimetics exenatide and vildagliptin on the survival of ischemic tissues | Tarasova, A. P.; Danilenko, L. M.; Sernov, L. N. |
| 2017 | Evaluation of cardioprotective effects of the incritinmimetics exenatideand vildagliptin in the experiment | Tarasova, A. P.; Danilenko, L. M.; Tatarenkova, I. A.; Khavansky, A. V.; Timokhina, A. S. |
| 2018 | Experimental approaches to the assessment of potential cardioprotective means with doxorubicin-associated cardiomyopathy | Danilenko, L. M.; Pokrovskiy, M. V.; Kotelnikova, A. S.; Timokhina, A. S.; Zhernakova, N. I. |
| 2016 | Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium | Danilenko, L. M.; Klochkova, G. N.; Kizilova, I. V.; Korokin, M. V. |
| 2016 | Pharmacological correction of L-NAME-induced oxide deficiency with derivatives of 3-(2,2,2-trimethylhydrazinium) propionate | Skachilova, S. Y.; Kesarev, O. G.; Danilenko, L. M.; Bystrova, N. A.; Dolzhikov, A. A. |
| 2015 | Pharmacological protection of the ischemic myocardium by derivatives of 3-(2,2,2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity | Skachilova, S. Y.; Danilenko, L. M.; Kesarev, O. G.; Kochkarov, I. S. |
| 2018 | Pharmacological screening of substances with cardioprotective effect in the group of 3-oxypyridine derivatives | Danilenko, L. M.; Skachilova, S. Ya.; Nadezhdin, S. V.; Timokhina, A. S.; Shcheblykina, O. V. |
| 2017 | Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of isolated rat heat | Kesarev, O. G.; Danilenko, L. M.; Pokrovskii, M. V.; Timokhina, A. S.; Khavanskii, A. V. |
